Partnerships
We are continually seeking opportunities with leading biopharmaceutical companies to identify areas of scientific synergy to address unmet medical needs. Through partnerships and collaboration, we can fully leverage Callavid to target and deliver other diverse drugs / hormones / therapies for wider patient benefit.
Calla Lily Clinical Care has been generously supported by Innovate UK – the UK government’s innovation agency. In 2022 & 2023, IUK confirmed additional grant funding for the company to advance its research & development efforts.
CLCC has designed an in-woman trial of our device with progesterone, working closely with the Clinical Trials Unit from University Hospitals Coventry & Warwickshire (UHCW). This is led by Professor Siobhan Quenby, our clinical co-lead and one of the world’s foremost authorities on miscarriage and preterm birth prevention. Siobhan led the highly-cited Lancet series (2021) on miscarriage and was co-applicant, major recruiter to and co-author on the two largest and most significant trials of vaginal progesterone to prevent miscarriage (PROMISE and PRISM). The results of these trials led to the UK’s NICE updating its miscarriage guideline, to now recommend women at high risk of miscarriage to take vaginal progesterone twice daily for up to 80 days – guidance that has subsequently been adopted in Australia and we believe is being closely followed in other countries, with potential to further expand the market opportunity for this indication
For more information about partnerships or other business development opportunities, please email us at info@callali.ly or telephone +44 (0) 20 7754 5400